CN101862469B - Chitosan derivative quick hemostasis granules and preparation method thereof - Google Patents
Chitosan derivative quick hemostasis granules and preparation method thereof Download PDFInfo
- Publication number
- CN101862469B CN101862469B CN 201010190260 CN201010190260A CN101862469B CN 101862469 B CN101862469 B CN 101862469B CN 201010190260 CN201010190260 CN 201010190260 CN 201010190260 A CN201010190260 A CN 201010190260A CN 101862469 B CN101862469 B CN 101862469B
- Authority
- CN
- China
- Prior art keywords
- chitosan
- hemostasis granules
- chitosan derivative
- quick hemostasis
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 73
- 230000023597 hemostasis Effects 0.000 title claims abstract description 59
- 239000008187 granular material Substances 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000000706 filtrate Substances 0.000 claims abstract description 13
- 238000003756 stirring Methods 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000001694 spray drying Methods 0.000 claims abstract description 9
- 238000003828 vacuum filtration Methods 0.000 claims abstract description 9
- 229910021529 ammonia Inorganic materials 0.000 claims abstract description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 51
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 18
- 239000002671 adjuvant Substances 0.000 claims description 15
- 230000006196 deacetylation Effects 0.000 claims description 14
- 238000003381 deacetylation reaction Methods 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 230000011987 methylation Effects 0.000 claims description 7
- 238000007069 methylation reaction Methods 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 7
- 238000010008 shearing Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 abstract description 20
- 206010052428 Wound Diseases 0.000 abstract description 19
- 239000000463 material Substances 0.000 abstract description 9
- 230000029663 wound healing Effects 0.000 abstract description 5
- 208000032843 Hemorrhage Diseases 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 4
- 210000001124 body fluid Anatomy 0.000 abstract description 3
- 239000010839 body fluid Substances 0.000 abstract description 3
- 241000894006 Bacteria Species 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 239000005714 Chitosan hydrochloride Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 239000008213 purified water Substances 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 230000000025 haemostatic effect Effects 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000002439 hemostatic effect Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940030225 antihemorrhagics Drugs 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229910052573 porcelain Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 208000023637 Multiple injury Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a chitosan derivative quick hemostasis granules and a preparation method thereof. The hemostasis granules are prepared by mixing chitosan hydrochloride, O- carboxymethyl chitosan and auxiliary material with purified water according to a certain proportion, sufficiently stirring and uniformly blending, adding ammonia to adjust the pH value of the mixed liquor to 7.0-9.0, carrying out vacuum filtration, and carrying out aseptic spray drying on the filtrate. The hitosan derivative quick hemostasis granules have the pH value suitable for the body fluid of a human body, has little irritation to the skin, can quickly stanch, has the functions of easing pain, promoting wound healing, inhibiting bacteria and the like, and is suitable for various wound hemostasis emergency treatments of trauma haemorrhage, including the hemostasis of large-area haemorrhage. In addition, the preparation method is simple and is easy for scale production.
Description
Technical field
The present invention relates to a kind of chitosan derivative quick hemostasis granules with hemostasis, antibacterial, antiinflammatory, promotion wound healing and preparation method thereof, belong to field of medical products, also belong to technical field of biological material.
Background technology
The main purpose of wound first aid is temporary Bleeding control, covering is bound up a wound as early as possible, and wound is isolated from the outside to reduce infection chance, is that good wound surface condition is created in debridement.Traditional wound hemostasis material mainly is first-aid kit, four-tailed bandage, tourniquet and binder etc., sometimes also has a large amount of aseptic dressings to be used for remedying the deficiency of first-aid kit wrapping hemostasis.A large amount of aseptic dressings are difficult to carry and the preservation of sterilizing; First-aid kit and four-tailed bandage only have aseptic scarf bandage and 1～2 block of medium and small dressing, and to the covering of large tracts of land wound and combined injury, multiple injury wound, haemostatic effect is not good enough.Therefore, exploitation is easy to carry about with one, has the novel wound hemostasis material of good haemostatic effect to become in recent years focus to the large tracts of land wound.
Lot of domestic and foreign research is verified, chitosan and derivant thereof have good hemostatic function, add the characteristic that they are intrinsic---nontoxic, no antigen, and have biocompatibility, bacteriostatic activity, promotion wound healing etc., give its superperformance as hemostatic material.But because the polarity of chitosan is poor, and be not suitable for being directly used in the wound hemostasis material.At present, the technology of making hemostatic material take chitosan and derivant thereof as raw material is open in a plurality of patents, but the raw material that adopts in these patents is chitosan itself, because chitosan is water insoluble, thereby relatively low with the interaction of wound location, can not fully realize its short more effect and anti-microbial property.Therefore, need chitosan just is suitable for the wound hemostasis material through chemical modification after strengthening its water solublity and biocidal property.
Summary of the invention
It is poor to the object of the invention is to remedy existing chitosan wound hemostasis material polarity, can not fully realize the shortcoming of its short more effect and anti-microbial property, a kind of energy quick-acting haemostatic powder is provided, good with skin-friendliness, chitosan derivative quick hemostasis granules of effects such as having good analgesia, promote wound healing, be antibacterial and preparation method thereof.
The objective of the invention is to be achieved by the following technical programs:
A kind of chitosan derivative quick hemostasis granules, it contains the quality percentage composition and is respectively 12.5～50% chitosan hydrochlorate and 12.5～50% O-CMC, and all the other are adjuvant; Described adjuvant comprises glycerol and propylene glycol at least, and the mass ratio of glycerol and propylene glycol is 1～4: 1.
The present invention also provides the preparation method of above-mentioned chitosan derivative quick hemostasis granules, may further comprise the steps:
(1) by the quality percentage composition of contained various components in the above-mentioned chitosan derivative quick hemostasis granules, with chitosan hydrochlorate, O-CMC and adjuvant, mix with the capacity pure water, then fully stirring makes it mix homogeneously and obtains mixed liquor, add in the mixed liquor after ammonia regulates pH value to 7.0～9.0, vacuum filtration obtains filtrate; Described adjuvant comprises glycerol and propylene glycol at least, and the mass ratio of glycerol and propylene glycol is 1～4: 1;
(2) filtrate is carried out aseptic spray drying, obtain chitosan derivative quick hemostasis granules.
The particle diameter of described chitosan derivative quick hemostasis granules is 0.1 μ m～10 μ m, and the pH value of the aqueous solution of this hemostasis granules of 1wt% is 7.0～9.0.
The molecular weight of described chitosan hydrochlorate is 1000～2,000,000, and deacetylation is that the pH value of this chitosan hydrochlorate aqueous solution of 80.0%～90.0%, 1wt% is 4.0～6.0.
The molecular weight of described O-CMC is 1000～2,000,000, and deacetylation is 70%～90%, and the carboxy methylation degree is that the substitution value of 0.5～1.5,6 hydroxyls is 0.5～1.0.
Be to adopt shearing mulser fully to stir to make it mix homogeneously in the step (1), whipping temp is 10～30 ℃.
To be 5 * 10 at pressure in the step (1)
5～7 * 10
5Vacuum filtration under the Pa.
Be to carry out aseptic spray drying in the sterile type drying machine in the step (2), obtaining particle diameter is the chitosan derivative quick hemostasis granules of 0.1 μ m～10 μ m.
Compared with prior art, advantage of the present invention is as follows:
(1) the present invention is take chitosan hydrochlorate and O-CMC as primary raw material, adds an amount of adjuvant and prepare chitosan derivative quick hemostasis granules, used chitosan hydrochlorate and O-CMC are all water-soluble, compare with chitosan, its polarity strengthens greatly, be conducive to strengthen the interaction of this hemostasis granules and wound location, thereby give full play to its bacteriostasis property and short more effect, can be directly used in wound location.
(2) chitosan derivative quick hemostasis granules of the present invention has the pH value (7.0～9.0) suitable with human body fluid, little to skin irritation, the energy quick-acting haemostatic powder, and have analgesia, promote wound healing, the effect such as antibacterial, be applicable to the wound hemostasis first aid of various traumatic hemorrhage, comprise the hemostasis of large-area hemorrhage.
(3) the present invention adopts shearing mulser to stir in preparation process, can guarantee that raw material fully dissolves in water, homogenize, shortens the production time, and technique is simple, is easy to large-scale production.
The specific embodiment
The present invention is further illustrated below by specific embodiment, but protection content of the present invention is not limited to following examples.
Embodiment 1
Get chitosan hydrochlorate 1.0kg, O-CMC 1.0kg, with glycerol 0.5kg and propylene glycol 0.5kg as adjuvant, mix with the 40.0kg pure water, adopt shearing mulser fully to stir at 15 ℃ and make it mix homogeneously, obtain mixed liquor.The molecular weight of above-mentioned chitosan hydrochlorate is 100,000～500,000, and deacetylation is that the pH value of this chitosan hydrochlorate aqueous solution of 82.0%, 1wt% is 4.3; The molecular weight of O-CMC is 100,000～500,000, and deacetylation is 70%, and the carboxy methylation degree is that the substitution value of 0.5～0.7,6 hydroxyls is 0.9.Adding in the above-mentioned mixed liquor after ammonia regulates pH of mixed to 7.0～7.5, is 5 * 10 with above-mentioned mixed liquor at pressure
5Vacuum filtration obtains filtrate under the Pa, at last filtrate being sent into sterile type sprays and carries out the operation of aseptic spray drying in the dried machine, making particle diameter is the aseptic micropowder of 0.1 μ m～10 μ m, be chitosan derivative quick hemostasis granules, the chitosan hydrochlorate comprising 33.3%, 33.3% O-CMC, 16.7% glycerol and 16.7% propylene glycol.The pH value of the aqueous solution of the above-mentioned hemostasis granules of 1wt% is 7.4.
Embodiment 2
Get chitosan hydrochlorate 0.75kg, O-CMC 0.75kg,, mix with the 40.0kg pure water as adjuvant with glycerol 0.75kg and propylene glycol 0.75kg, fully stir and make it mix homogeneously, obtain mixed liquor.The molecular weight of above-mentioned chitosan hydrochlorate is 500,000～1,000,000, and deacetylation is that the pH value of this chitosan hydrochlorate aqueous solution of 85.0%, 1wt% is 4.7; The molecular weight of O-CMC is 500,000～1,000,000, and deacetylation is 75%, and the carboxy methylation degree is that the substitution value of 0.7～0.9,6 hydroxyls is 0.7.Adding in the above-mentioned mixed liquor after ammonia regulates pH of mixed to 7.6～8.0, is 7 * 10 with above-mentioned mixed liquor at pressure
5Vacuum filtration obtains filtrate under the Pa, at last filtrate being sent into sterile type sprays and carries out the operation of aseptic spray drying in the dried machine, making particle diameter is the aseptic micropowder of 0.1 μ m～10 μ m, be chitosan derivative quick hemostasis granules, the chitosan hydrochlorate comprising 25.0%, 25.0% O-CMC, 25.0% glycerol and 25.0% propylene glycol.The pH value of the aqueous solution of the above-mentioned hemostasis granules of 1wt% is 7.8.
Embodiment 3
Get chitosan hydrochlorate 0.75kg, O-CMC 1.25kg, with glycerol 0.5kg and propylene glycol 0.5kg as adjuvant, mix with the 40.0kg pure water, adopt shearing mulser fully to stir at 20 ℃ and make it mix homogeneously, obtain mixed liquor.The molecular weight of above-mentioned chitosan hydrochlorate is 1,000,000～1,500,000, and deacetylation is that the pH value of this chitosan hydrochlorate aqueous solution of 87.0%, 1wt% is 5.1; The molecular weight of O-CMC is 1,000,000～1,500,000, and deacetylation is 80%, the carboxy methylation degree is that the substitution value of 0.9～1.2,6 hydroxyls is 0.8.Adding in the above-mentioned mixed liquor after ammonia regulates pH of mixed to 8.1～8.5, is 5 * 10 with above-mentioned mixed liquor at pressure
5Pa～7 * 10
5Vacuum filtration obtains filtrate under the Pa, at last filtrate being sent into sterile type sprays and carries out the operation of aseptic spray drying in the dried machine, make particle diameter in the aseptic micropowder of 0.1 μ m～10 μ m, be chitosan derivative quick hemostasis granules, the chitosan hydrochlorate comprising 25.0%, 41.6% O-CMC, 16.7% glycerol and 16.7% propylene glycol.The pH value of the aqueous solution of the above-mentioned hemostasis granules of 1wt% is 8.2.
Embodiment 4
Get chitosan hydrochlorate 1.25kg, O-CMC 0.75kg, with glycerol 0.5kg and propylene glycol 0.5kg as adjuvant, mix with the 40.0kg pure water, adopt shearing mulser fully to stir at 30 ℃ and make it mix homogeneously, obtain mixed liquor.The molecular weight of above-mentioned chitosan hydrochlorate is 1,500,000～2,000,000, and deacetylation is that the pH value of this chitosan hydrochlorate aqueous solution of 88.0%, 1wt% is 5.4; The molecular weight of O-CMC is 1,500,000～200,000, and deacetylation is 85%, the carboxy methylation degree is that the substitution value of 1.2～1.5,6 hydroxyls is 0.6.Adding in the above-mentioned mixed liquor after ammonia regulates pH of mixed to 8.6～9.0, is 6 * 10 with above-mentioned mixed liquor at pressure
5Vacuum filtration obtains filtrate under the Pa, at last filtrate being sent into sterile type sprays and carries out the operation of aseptic spray drying in the dried machine, make particle diameter in the aseptic micropowder of 0.1 μ m～10 μ m, be chitosan derivative quick hemostasis granules, the chitosan hydrochlorate comprising 41.6%, 25% O-CMC, 16.7% glycerol and 16.7% propylene glycol.The pH value of the aqueous solution of the above-mentioned hemostasis granules of 1wt% is 8.6.
Can adopt glycerol and propylene glycol as adjuvant among the present invention, can also adopt or add other functional adjuvants.
Chitosan derivative quick hemostasis granules of the present invention is carried out bacteriostatic experiment, observe the growing state of bacterium colony on hemostasis granules behind 16～20h.The results are shown in Table 1:
Table 1. chitosan derivative quick hemostasis granules bacteriostatic experiment result
Annotate :+expression has colony growth, and-expression is without colony growth.
Study chitosan derivative quick hemostasis granules of the present invention to the haemostatic effect of dog biceps femoris wound surface, with starch in contrast, experimental result sees Table 2:
The haemostatic effect experimental result of table 2. chitosan derivative quick hemostasis granules
Adopt the porcelain plate method to study chitosan derivative quick hemostasis granules of the present invention to the impact of rabbit clotting time, with starch and blank in contrast, method is as follows: in a pit of porcelain plate, the normal saline solution 0.1ml that adds the 1wt% hemostasis granules, select in addition two pits, add respectively equivalent 1wt% starch normal saline solution and normal saline.All add 1 of 3wt% calcium chloride solution in pit, medicinal liquid and calcium chloride solution mixing, add simultaneously 3 of blood that contain anticoagulant with the pin of nail on plank in each pit again, immediately timing is rapidly with 10 mixings of pin stirring.Later per half a minute passes blood with pin and pushes away gently and choose once, for the beginning blood coagulation, when promoting clot, can expose the porcelain plate white background and be blood and solidify fully when the blood streak occurring.From add anticoagulated blood to the time that blood solidifies fully be clotting time.The results are shown in Table 3:
Table 3. chitosan derivative quick hemostasis granules is on the result that affects of rabbit clotting time
By above experimental result as can be known, chitosan derivative quick hemostasis granules of the present invention has good bacteriostasis property, the energy quick-acting haemostatic powder, and have and the suitable pH value of human body fluid, therefore can be used as hemostatic material is directly used in wound location.
Claims (8)
1. chitosan derivative quick hemostasis granules is characterized in that: this quick hemostasis granules contains the quality percentage composition and is respectively 12.5 ~ 50% chitosan hydrochlorate and 12.5 ~ 50% O-CMC, and all the other are adjuvant; Described adjuvant comprises glycerol and propylene glycol at least, and the mass ratio of glycerol and propylene glycol is 1 ~ 4:1; The molecular weight of described chitosan hydrochlorate is 1000 ~ 2,000,000, and deacetylation is that the pH value of this chitosan hydrochlorate aqueous solution of 80.0% ~ 90.0%, 1wt% is 4.0 ~ 6.0; The molecular weight of described O-CMC is 1000 ~ 2,000,000, and deacetylation is 70% ~ 90%, and the carboxy methylation degree is that the substitution value of 0.5 ~ 1.5,6 hydroxyls is 0.5 ~ 1.0.
2. chitosan derivative quick hemostasis granules according to claim 1, it is characterized in that: the particle diameter of described chitosan derivative quick hemostasis granules is 0.1 μ m ~ 10 μ m, and the pH value of the aqueous solution of this hemostasis granules of 1wt% is 7.0 ~ 9.0.
3. the preparation method of the described chitosan derivative quick hemostasis granules of claim 1 is characterized in that may further comprise the steps:
(1) by the quality percentage composition of contained various components in the described chitosan derivative quick hemostasis granules of claim 1, with chitosan hydrochlorate, O-CMC and adjuvant, mix with the capacity pure water, then fully stirring makes it mix homogeneously and obtains mixed liquor, add in the mixed liquor after ammonia regulates pH value to 7.0 ~ 9.0, vacuum filtration obtains filtrate; Described adjuvant comprises glycerol and propylene glycol at least, and the mass ratio of glycerol and propylene glycol is 1 ~ 4:1;
(2) filtrate is carried out aseptic spray drying, obtain chitosan derivative quick hemostasis granules.
4. the preparation method of described chitosan derivative quick hemostasis granules according to claim 3, it is characterized in that: the molecular weight of chitosan hydrochlorate is 1000 ~ 2 described in the step (1), 000,000, deacetylation is that the pH value of this chitosan hydrochlorate aqueous solution of 80.0% ~ 90.0%, 1wt% is 4.0 ~ 6.0.
5. the preparation method of described chitosan derivative quick hemostasis granules according to claim 3, it is characterized in that: the molecular weight of O-CMC is 1000 ~ 2 described in the step (1), 000,000, deacetylation is 70% ~ 90%, the carboxy methylation degree is that the substitution value of 0.5 ~ 1.5,6 hydroxyls is 0.5 ~ 1.0.
6. the preparation method of described chitosan derivative quick hemostasis granules according to claim 3, it is characterized in that: be to adopt shearing mulser fully to stir to make it mix homogeneously in the step (1), whipping temp is 10 ~ 30 ℃.
7. the preparation method of described chitosan derivative quick hemostasis granules according to claim 3 is characterized in that: be to be 5 * 10 at pressure in the step (1)
5~ 7 * 10
5Vacuum filtration under the Pa.
8. the preparation method of described chitosan derivative quick hemostasis granules according to claim 3, it is characterized in that: be to carry out aseptic spray drying in the sterile type drying machine in the step (2), obtaining particle diameter is the chitosan derivative quick hemostasis granules of 0.1 μ m ~ 10 μ m.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010190260 CN101862469B (en) | 2010-05-28 | 2010-05-28 | Chitosan derivative quick hemostasis granules and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010190260 CN101862469B (en) | 2010-05-28 | 2010-05-28 | Chitosan derivative quick hemostasis granules and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101862469A CN101862469A (en) | 2010-10-20 |
| CN101862469B true CN101862469B (en) | 2013-03-13 |
Family
ID=42954519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010190260 Expired - Fee Related CN101862469B (en) | 2010-05-28 | 2010-05-28 | Chitosan derivative quick hemostasis granules and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101862469B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102772785A (en) * | 2012-08-14 | 2012-11-14 | 中国人民解放军第四军医大学 | Composite medicine and ointment for hemostasis and preparation methods of composite medicine and ointment |
| KR101864465B1 (en) | 2014-01-21 | 2018-06-04 | 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 | Micro particles administered in vivo through an endoscopic catheter |
| GB201404944D0 (en) * | 2014-03-19 | 2014-04-30 | Medtrade Products Ltd | Wound dressing |
| CN103893204B (en) * | 2014-04-03 | 2016-05-11 | 石家庄亿生堂医用品有限公司 | A kind of preparation method of chitosan hydrochloride calcium styptic powder |
| CN104840483A (en) * | 2015-06-08 | 2015-08-19 | 济南博创医药科技有限公司 | Medicine composition for treating skin wounds and medicinal preparation thereof |
| CN108815563A (en) * | 2018-07-23 | 2018-11-16 | 天津市长江医疗器械有限公司 | A kind of gelatin hemostatic material and its preparation process |
| CN110755674B (en) * | 2019-11-27 | 2022-04-19 | 盐城市盐康医疗器材有限公司 | Hemostatic powder and preparation method thereof |
| CN111135338A (en) * | 2019-12-31 | 2020-05-12 | 瑞希(重庆)生物科技有限公司 | Hemostatic gel and preparation method thereof |
| CN113521379A (en) * | 2021-07-12 | 2021-10-22 | 重庆大清海德生物技术有限公司 | Preparation method of large-wound chitosan hemostatic particles |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101547686A (en) * | 2005-07-13 | 2009-09-30 | 赫姆孔公司 | Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from chitosan and including a polymer mesh material of poly-4-hydroxy butyrate |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030093114A1 (en) * | 2001-11-13 | 2003-05-15 | Melvin Levinson | Method for effecting hemostasis |
-
2010
- 2010-05-28 CN CN 201010190260 patent/CN101862469B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101547686A (en) * | 2005-07-13 | 2009-09-30 | 赫姆孔公司 | Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from chitosan and including a polymer mesh material of poly-4-hydroxy butyrate |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101862469A (en) | 2010-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101862469B (en) | Chitosan derivative quick hemostasis granules and preparation method thereof | |
| AU2006329660B2 (en) | Hemostatic material | |
| CN103230617B (en) | Collagen/chitosan micro-nano fiber composite hemostatic membrane material and preparation method thereof | |
| CN101053669B (en) | Water soluble chitosan-based hemostatic wound-healing marine sponge and its preparation method and application | |
| CN106620824B (en) | A kind of preparation method of high-efficiency antimicrobial compound hemostatic sponge | |
| CN106496357B (en) | A kind of O- quaternary ammonium salt-N- alkylated chitosan and the preparation method and application thereof | |
| CN102526795A (en) | Chitosan-based styptic sponge and preparation method thereof | |
| CN107243086A (en) | A kind of absorbable compound hemostatic powder and preparation method thereof | |
| CN105963766A (en) | Absorbable antibacterial hemostatic microsphere, preparation method and application thereof | |
| CN106110383A (en) | A kind of chitosan alginate dressing and freeze-drying process thereof | |
| CN103260633B (en) | The agent for stanching of extract containing golden moss | |
| CN111450306B (en) | External nano hydroxyapatite/polydopamine wet adhesion type styptic powder and preparation method thereof | |
| Wang et al. | An antibacterial and antiadhesion in situ forming hydrogel with sol–spray system for noncompressible hemostasis | |
| CN110507842A (en) | A kind of bacteria cellulose/hyaluronic acid/epsilon-polylysine functional form dressing and preparation method thereof | |
| Ekambaram et al. | Fabrication of wheatgrass incorporated PCL/chitosan biomimetic nanoscaffold for skin wound healing: In vitro and In silico analysis | |
| He et al. | Multifunctional Bletilla striata polysaccharide/copper/peony leaf sponge for the full-stage wound healing | |
| CN104208741A (en) | Chitosan based adhesive bandage | |
| CN105561370A (en) | Novel hemostatic material and preparation method thereof | |
| CN112870430B (en) | Composite gel hemostatic powder based on natural polysaccharide, and preparation method and application thereof | |
| CN110124082A (en) | Swelling type medical bio gel filler based on Polysaccharide from Portulaca oleracea and chromocor extract | |
| CN107033397A (en) | A kind of preparation method of calcium chelant carboxyl chitosan/organo montmorillonite gel rubber material | |
| US11890392B2 (en) | Absorbable bone wax and preparation method thereof | |
| CN106822984A (en) | A kind of biocompatibility is strong, preventing tissue is adhered, the degradable absorption antibacterial anti hemorrhagic composition of wound healing promoting and application thereof | |
| CN116212103A (en) | Chitosan gel dressing for promoting healing as well as preparation method and application thereof | |
| CN107715167A (en) | Chitosan-based hemostatic paste and preparation method as bone wax substitute |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 430074, 169 Wuhan, East Lake New Technology Development Zone, Wuhan, Hubei, China Applicant after: Wuhan Humanwell Medical Supplies Co., Ltd. Address before: 430074, A, block 1, international enterprise center, 406 Optics Valley Avenue, East Lake New Technology Development Zone, Hubei, Wuhan, China Applicant before: Wuhan Ruier Biotechnology Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: WUHAN RUIER BIOTECHNOLOGY CO., LTD. TO: WUHAN RENFU MEDICAL PRODUCTS CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 430074, 169 Wuhan, East Lake New Technology Development Zone, Wuhan, Hubei, China Patentee after: People's good fortune Pharmaceutical Group medical supplies company limited Address before: 430074, 169 Wuhan, East Lake New Technology Development Zone, Wuhan, Hubei, China Patentee before: Wuhan Humanwell Medical Supplies Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130313 Termination date: 20180528 |